Document Type
Article
Publication Date
2-1-2023
Original Citation
Snyder J,
Casey K,
Galecki A,
Harrison D,
Jayarathne H,
Kumar N,
Macchiarini F,
Rosenthal N,
Sadagurski M,
Salmon A,
Strong R,
Miller R,
Ladiges W.
Canagliflozin retards age-related lesions in heart, kidney, liver, and adrenal gland in genetically heterogenous male mice. Geroscience. 2022;45(1):385-97.
Keywords
JMG, Mice, Male, Female, Animals, Canagliflozin, Hypoglycemic Agents, Liver, Kidney, Adrenal Glands
JAX Source
Geroscience. 2022;45(1):385-97.
ISSN
2509-2723
PMID
35974129
DOI
https://doi.org/10.1007/s11357-022-00641-0
Grant
This work was funded by NIA grants, U01-AG022303, U01-AG022308, P30-AG024824, AG022307, and AG013319. RS is supported by a Senior Research Career Scientist Award from the Department of Veterans Affairs Office of Research and Development.
Abstract
Canagliflozin (Cana), a clinically important anti-diabetes drug, leads to a 14% increase in median lifespan and a 9% increase in the 90th percentile age when given to genetically heterogeneous male mice from 7 months of age, but does not increase lifespan in female mice. A histopathological study was conducted on 22-month-old mice to see if Cana retarded diverse forms of age-dependent pathology. This agent was found to diminish incidence or severity, in male mice only, of cardiomyopathy, glomerulonephropathy, arteriosclerosis, hepatic microvesicular cytoplasmic vacuolation (lipidosis), and adrenal cortical neoplasms. Protection against atrophy of the exocrine pancreas was seen in both males and females. Thus, the extension of lifespan in Cana-treated male mice, which is likely to reflect host- or tumor-mediated delay in lethal neoplasms, is accompanied by parallel retardation of lesions, in multiple tissues, that seldom if ever lead to death in these mice. Canagliflozin thus can be considered a drug that acts to slow the aging process and should be evaluated for potential protective effects against many other late-life conditions.
Comments
This article is licensed under a Creative Com- mons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Crea- tive Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.